Case Report: A novel TP53 mutation in a patient with quadruple wild-type gastrointestinal stromal tumor

Article Genetics & Heredity

A novel fusion between CDC42BPB and ALK in a patient with quadruple wild-type gastrointestinal stromal tumor

Wen Huang et al.

Summary: This study reports a rare case of quadruple wild-type GIST, in which the patient showed both ALK-CDC42BPB fusion and ALK overexpression.

MOLECULAR GENETICS & GENOMIC MEDICINE (2022)

Add to Collection

Article Oncology

Identification of a novel FGFR2-KIAA1217 fusion in esophageal gastrointestinal stromal tumours: A case report

Yuehao Luo et al.

Summary: This case report describes a rare esophageal gastrointestinal stromal tumor (GIST) with an FGFR2-KIAA1217 fusion. The study emphasizes the importance of intensive genetic analysis for wild-type KIT/PDGFRA GISTs.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Pathology

Next-generation sequencing demonstrates the rarity of short kinase variants specific to quadruple wild-type gastrointestinal stromal tumours

Newton A. C. S. Wong et al.

Summary: The study aimed to identify a potential therapeutic target for qWT GISTs as there is no specific biomarker or genetic signal known for these tumors. Through NGS analysis, rare short kinase variants specific to qWT GISTs were found, indicating that the current definition of qWT GISTs may cover a heterogenous population.

JOURNAL OF CLINICAL PATHOLOGY (2021)

Add to Collection

Review Oncology

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Jiahao Hu et al.

Summary: TP53 is a critical tumor-suppressor gene commonly mutated in human cancers, with potential oncogenic properties when mutated. Treatments for cancers with mutant p53 involve targeting mutant p53 directly, restoring wild-type functions, and exploring synthetic lethal interactions with mutant p53 for therapeutic benefits. Additionally, disrupting noncoding RNA networks may have potential synthetic lethal effects in cancers with p53 mutations.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Gastrointestinal stromal tumours

Jean-Yves Blay et al.

Summary: Gastrointestinal stromal tumours (GIST) are rare malignancies with 80% of cases having KIT or PDGFRA activating mutations. Localized GIST can be cured through surgery, while advanced resistant GIST with resistance mutations require treatment with new drugs.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Article Oncology

P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma

Yohei Sekino et al.

Summary: This study investigated the potential role of p53 in sunitinib resistance and as a predictive marker in mRCC. The findings suggest that p53 may be involved in sunitinib resistance and represent a valuable marker for sunitinib treatment in mRCC, with p53-positive cases tending to be associated with poor progression-free survival after sunitinib treatment.

ANTICANCER RESEARCH (2021)

Add to Collection

Article Oncology